On 19th March, Sinew Pharma announced that its new drug SNP-630 for the treatment of non-alcoholic steatohepatitis has been accepted for presentation at the American Association of Pharmaceutical Scientists (AAPS 2022 PHARMSCI 360) in animal trials and Phase II human clinical trials.
SNP-630 is a new ingredient for the treatment of steatohepatitis with strong pharmacological activity and more than four active metabolites that have been proven in in vivo trials to treat steatohepatitis with a high safety profile, acting directly on the liver to reduce liver lipids and liver fibrosis biomarkers.
Among them, the active metabolite of SNP-630 has completed a Phase II clinical trial with 36 subjects divided into high and low dose groups and the results of the interim analysis showed significant clinical efficacy compared to the pre-drug period, successfully achieving the goal of treating steatohepatitis.
SNP-630 has also completed a Phase I clinical trial in Taiwan and the data shows that SNP-630 has a high safety profile in humans and is currently in Phase II clinical planning. In addition, SNP-630 showed significant improvement in liver inflammation, hepatic steatosis and fibrosis in treated mice, as well as a significant reduction in fibrosis-related biomarkers and a reduction in liver triglyceride levels in mice treated with SNP-630 and active metabolites.
SNP-630, a new drug for non-alcoholic steatohepatitis, was accepted by the 2022 American Pharmacognosy Conference for its anti-inflammatory and anti-fibrotic efficacy in animal and phase II human clinical trials of active metabolites, and the clinical data was presented at the conference, according to Shinyo.
According to the GlobalData report, the nonalcoholic steatohepatitis market in the US, Japan and the EU (France, Germany, Italy, Spain and the UK) is forecast to grow at a compound annual rate of 45% over the next 10 years, while Deutsche Bank and Evaluate Pharma forecast the global nonalcoholic steatohepatitis drug market to be US$35-40 billion by 2025. US$35-40 billion by 2025.
More information please visit Sinew Pharma
